LGVN
USDLongeveron Inc. Class A Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$0.820
Kõrge
$0.820
Madal
$0.800
Maht
0.38M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
16.8M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.95M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions,
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHSFull enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II)
Seotud aktsiad
FLDDU
FTAC Emerald Acquisition Corp. Unit
WKC
World Kinect Corporation
KTRA
Kintara Therapeutics Inc.
RLX
RLX Technology Inc. American Depositary Shares each representing the right to receive one (1) ordinary share
GL
Globe Life Inc.
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.